DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

Subtle Medical closes RSNA with CE mark and FDA clearance of PET AI solution Speeds up scans by factor of four, enhanced image quality

Siemens unveils syngo Virtual Cockpit software for CT, MR and PET at RSNA Offers remote expert technicians when needed

South African NTP Radioisotopes facility reopens following year-long closure Will help alleviate worldwide shortages of Mo-99 and other isotopes

Total-body PET scanner produces landmark human images First ever simultaneously captured 3-D image of the entire human body

TeamBest companies to acquire ABT Molecular Imaging, launch Best ABT Bringing greater expertise to smaller cyclotron technology

Dr. Bernhard Sixt Edinburgh Molecular Imaging appoints as new Chief Executive Officer

Missouri reactor becomes sole US domestic source of I-131 A vital radioisotope in the fight against thyroid cancer and hyperthyroidism

Cardinal Health to distribute IRE ELiT's 68-Ga generators Aiming to alleviate access shortages with Galli Eo generators

Zionexa partners with Columbia PET Center on development of EstroTep Identifies estrogen receptor status to diagnose metastatic breast cancer

Canada to build medical isotope research and development center Will act as a regional source for isotopes, including Tc-99m

Cerveau Technologies is expanding its
production network for greater access
to research on the impact of a novel
imaging agent for neurodegenerative
diseases such as Alzheimer's disease

Cerveau Technologies to expand production network for research on novel tau imaging agent

by John R. Fischer , Staff Reporter
Cerveau Technologies Inc. is setting up camp in six new places throughout the U.S. thanks to a growing interest in a developmental and investigational tau imaging agent.

The Boston-based enterprise is expanding its production network to enhance access and opportunities in research for [18F]MK-6240, a novel contrast agent utilized in PET scans to assess the status and progression of neurofibrillary tangles (NFTs) within the brain as part of several neurodegenerative conditions such as Alzheimer’s disease.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

“Cerveau is focused on increasing access to the transformative technologies that we believe have the potential to advance brain health,” Rick Hiatt, president and chief executive officer of Cerveau Technologies, said in a statement.

NFTs are composed of aggregated tau protein, the hallmarks of Alzheimer’s and other forms of dementia.

Consisting of 10 production sites throughout the U.S., Canada, Australia and Belgium, Cerveau has qualified six additional ones over the last few weeks in Hayward, California; Houston, Texas; Phoenix, Arizona; and Birmingham, Alabama, as well as at John Hopkins University in Baltimore, Maryland and Columbia University in New York City.

In addition, twenty other sites are undergoing capital expansion, technology transfer and startup processes to provide greater support to a variety of research and therapy clinical trial initiatives worldwide. Their locations include one in Canada, three in the U.S., four in Japan, four in Australia, four in Europe and four in China.

The growth of its production network, according to Hiatt, will support imaging biomarkers licensed by Cerveau and its partners for research and development.

“This expansion of the biomarker production network underscores our commitment to the broader scientific research community and our support of industry’s initiatives to combat neurodegenerative disorders,” he said.

Cerveau Technologies formed a number of partnerships this year to promote research for [18F]MK-6240, including one with the Kobe City Hospital Organization in Japan; another with Massachusetts General Hospital (MGH); and one with the University of Pittsburgh.

Hiatt did not respond for comment.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.